Head-to-head · WeighScore
Candor Rx vs Omada Health
The verdict
Candor Rx takes it — 74.8/100 to 55.6/100.
Candor Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Candor Rx (candorrx.com) is a GLP-1 telehealth service offering compounded semaglutide and tirzepatide with flat, dose-independent pricing marketed as '$95/month, any dose, forever.' Semaglutide starts as…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Candor Rx | Omada Health |
|---|---|---|
| WeighScore | 74.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #60 | #435 |
| Semaglutide | $99/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $149/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #60 · C
Strengths
- Flat, dose-independent pricing marketed as '$95/month, any dose, forever' — no upcharge as your dose increases
- Low starting prices: compounded semaglutide as low as $99/mo and tirzepatide as low as $149/mo
- Medication ships in about 48 hours and you can cancel anytime
- Simple, transparent GLP-1 focus with pricing shown up front before signup
Where it loses points
- Prescribing medical group and compounding pharmacy are not named on the site
- States of operation are not published; confirm eligibility during intake
- No LegitScript certification is displayed
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.